Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients

Adel Abdel-Moneim, Alaa Abood, Mohamed Abdel-Gabaar, Mohamed I Zanaty, Mohamed Ramadan, Adel Abdel-Moneim, Alaa Abood, Mohamed Abdel-Gabaar, Mohamed I Zanaty, Mohamed Ramadan

Abstract

Introduction: New regimens involving direct-acting antiviral agents (DAAs) have recently been approved for the treatment of hepatitis C virus (HCV) genotype 4 (GT4). The current study aims to assess the efficacy and safety of sofosbuvir (SOF) with pegylated interferon (PegINF)/ribavirin (RBV) for chronic HCV GT4 patients at the beginning of the interferon-free era.

Material and methods: Between March 2015 and November 2015, 99 patients (59 naïve and 40 experienced) infected with HCV GT4 were enrolled in the study. Eligible patients received daily oral 400 mg SOF, RBV (body weight: < 75 kg, 1000 mg; < 75 kg, 1200 mg), the dose modified according to patient tolerability, plus 180 μg PegINFα-2 once weekly for 12 weeks.

Results: Among the patient cohort, sustained virological response 12 weeks after the end of treatment (SVR12) was achieved by 88% (87/99) of all patients, by 93% (55/59) of naïve patients and by 80% (32/40) of experienced patients. Regarding treatment failure, the data recorded 12% (12/99) of patients (4 null responses and 8 relapsers). Otherwise, the most common adverse events observed during the study included headache, nausea, fatigue, dyspnea, influenza-like illness, anemia, and leukopenia.

Conclusions: SOF combination-based therapies were considered promising choice regimens for chronic HCV infection. The present findings suggest that the combination of the SOF/PegINF/RBV regimen was effective for Egyptian patients with HCV GT4. The recorded adverse events and viral outcome revealed the high need for further efforts to minimize the side effects of the current regimen and/or replace PegINF with additional potent DAA(s) to increase SVR12 to achieve 100%.

Keywords: Egyptian patients; HCV genotype 4; Peg-interferon α-2; ribavirin; sofosbuvir.

Figures

Fig. 1
Fig. 1
Study flowchart

References

    1. Waked I, Doss W, El-Sayed MH, et al. The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol. 2014;15:45–52.
    1. Anagnostou O, Manolakopoulos S, Bakoyannis G, et al. Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study. Hippokratia. 2014;18:57–64.
    1. Zoulim F, Liang TJ, Gerbes AL, et al. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut. 2015;64:1824–1833.
    1. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887.
    1. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–1877.
    1. Bourliere M, Oules V, Ansaldi C, et al. Sofosbuvir as backbone of interferon free treatments. Dig Liver Dis. 2014;46:S212–220.
    1. Koff RS. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2014;39:478–487.
    1. Lemoine M, Thursz M, Hepatitis C. A Global Issue: Access to Care and New Therapeutic and Preventive Approaches in Resource-Constrained Areas. Semin Liver Dis. 2014;34:89–97.
    1. EASL Recommendations on treatment of hepatitis C. 2015. Available at: of-hepatitis-c-2015 (Accessed: 4 August 2016.
    1. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment naïve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomized, multicenter phase 2 trial. Lancet. 2013;381:2100–2107.
    1. Elsharkawy A, Fouad R, El Akel W. Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt. Aliment Pharmacol Ther. 2017;45:681–687.
    1. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis patients with HIV/HCV co-infection. Hepatology. 2005;43:1317–1325.
    1. Esmat G, El Kassas M, Hassany M, et al. Optimizing treatment for HCV genotype 4: PEG-IFN alfa 2a vs. PEG-IFN alfa 2b; the debate continues. Liver Int. 2014;34:24–28.
    1. Rodriguez-Torres M, Lawitz E, Kowdley KV, et al. Sofosbuvir (GS-7977) plus peg-interferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol. 2013;58:663–668.
    1. Foster GR, Pianko S, Cooper C, et al. Sofosbuvir + Peg-interferon/Ribavirin for 12 weeks vs Sofosbuvir + Ribavirin for 16 or 24 weeks in Genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: The BOSON study. J Hepatol. 2015;62:S259–S260.
    1. Salama H, Zekri AR, Medhat E, et al. Effect of Sofosbuvir, Brand Drug (Sovaldi) versus generic (MPI Viropack) in treating chronic HCV genotype 4 infection among Egyptian patients. EC Gastroenterology and Digestive System. 2016;1.2:56–61.
    1. Ruane PJ, Ain D, Stryker R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol. 2015;62:1040–1046.
    1. Riad SE, El-Ekiaby N, Mekky RY, et al. Expression signature of microRNA-155 in hepatitis C virus genotype 4 infection. Biomed Rep. 2015;3:93–97.
    1. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008;49:634–635.
    1. Buti M, Esteban R. Management of direct antiviral agent failures. Clin Mol Hepatol. 2016;22:432–438.
    1. Lashin AH, Shaheen YA, Metwally MA, et al. Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with pegylated interferon and ribavirin. Indian J Gastroenterol. 2013;32:316–323.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere